Structure Therapeutics (NASDAQ:GPCR) Shares Down 4% - Here's Why

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) dropped 4% on Thursday . The stock traded as low as $20.88 and last traded at $20.92. Approximately 146,742 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 843,992 shares. The stock had previously closed at $21.79.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday. William Blair assumed coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating for the company. HC Wainwright reduced their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Citigroup began coverage on Structure Therapeutics in a research report on Friday, May 2nd. They issued a "buy" rating and a $60.00 target price on the stock. Finally, JMP Securities reissued a "market outperform" rating and set a $89.00 price target on shares of Structure Therapeutics in a research report on Monday. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $76.17.

Structure Therapeutics Trading Down 3.3%

The stock has a 50-day moving average price of $23.46 and a 200 day moving average price of $24.04. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -24.23 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Jones Financial Companies Lllp boosted its stake in shares of Structure Therapeutics by 29.8% in the fourth quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company's stock worth $115,000 after acquiring an additional 971 shares during the last quarter. Assetmark Inc. boosted its stake in Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after purchasing an additional 953 shares during the last quarter. M&T Bank Corp boosted its stake in Structure Therapeutics by 100.0% during the 4th quarter. M&T Bank Corp now owns 18,110 shares of the company's stock worth $492,000 after purchasing an additional 9,055 shares during the last quarter. Candriam S.C.A. grew its holdings in shares of Structure Therapeutics by 59.6% during the fourth quarter. Candriam S.C.A. now owns 215,421 shares of the company's stock worth $5,842,000 after buying an additional 80,421 shares in the last quarter. Finally, Vestcor Inc acquired a new stake in shares of Structure Therapeutics in the fourth quarter valued at about $127,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.